The Europe parenteral nutrition market size surpassed USD 2.25 billion in 2025 and is predicted to reach around USD 3.81 billion by 2035, registering a CAGR of 5.4% from 2026 to 2035. A rapidly aging European population and technological innovations in formulation and safety are accelerating the demand for parenteral nutrition in Europe.

Europe Parenteral Nutrition Market Statical Scope

The World Health Organization (WHO) has urged global schools to promote healthy eating for children to further develop healthy dietary habits for life. The WHO has approached schools to adopt evidence-based policies and interventions to ensure the availability and access to nutritious and healthy food and beverages for children.

However, the European Commission launched a new framework to simplify instructions on clinical equipment. The major government and regulatory initiatives are the EU medical device electronic regulation, the EU e-pharmacy directive, Team Europe's Nutrition Pledge, and the ERA4Health "NutriBrain" Program.

Europe Parenteral Nutrition Market Share, By Nutrient Type, 2025 (%)

• Single Dose Amino Acid Solution -32% - The single dose amino acid solution segment dominated the market in 2025, with a share of 32%, owing to its features of providing exact essential and non-essential amino acids needed to maintain the patient's nitrogen balance. There is a surging need for patient-specific protein supplementation and modern clinical care. It boosts muscle retention, tissue repair, and overall recovery outcomes.
• Parenteral Lipid Emulsion - The parenteral lipid emulsion segment held a 25% share and is expected to grow in the coming years, driven by the growing need for long-term and intensive caloric supplementation. The lipids are used as highly concentrated and non-carbohydrate energy sources. This use is driven by increased admissions in surgical wards and intensive care units.

Europe Parenteral Nutrition Market Share, By Stage Type, 2025 (%)

• Adult - The adult segment dominated the market in 2025 with a share of 70%, supported by the importance of parenteral nutrition in oncology applications, gastrointestinal disorders, and severe dysphagia. Continuous intravenous nutritional support is needed in case of malnutrition caused by advanced gastrointestinal malignancies, chemotherapy, and severe cachexia. Parenteral nutrition among adults is led by the rising global cases of short bowel syndrome, Crohn's disease, chronic bowel obstructions, and ulcerative colitis.
• Pediatrics - The pediatrics segment held a 30% share and is expected to grow in the coming years, driven by the requirements of higher early doses of lipid emulsions and amino acids among preterm and low-birth-weight infants to ensure brain development. The elevated pediatric cancer rates and metabolic conditions require critical care. The pediatric population also requires immediate nutritional interventions during active hospital treatments.

Europe Parenteral Nutrition Market Share, By Indication, 2025 (%)

• Cancer Care - The cancer care segment dominated the market in 2025, with a share of 40%, owing to the heavy adoption of pre-mixed and multi-chamber bag systems by hospitals. Targeted formulations and product portfolios offer specialized lipid emulsions, amino acid profiles, and immunonutrition blends. They are designed to treat specific cancer types and treatment stages.
• Malabsorption/GI Disorder/Diarrhea - The malabsorption/GI disorder/diarrhea segment held a 10% share and is expected to grow in the coming years, driven by a shift of hospitals and clinics to ready-to-use multi-chamber bags to reduce errors and gain efficiency. These systems are used to isolate amino acids, lipids, and glucose until activation. They also reduce hospital compounding and preparation times and medication compounding errors.

Europe Parenteral Nutrition Market Share, By Sales Channel, 2025 (%)

• Institutional - The institutional segment dominated the market in 2025, with a share of 75%, accelerated by the increased efforts of acute and critical care settings to stabilize patients who cannot tolerate oral or enteral feeding. There is an increased use of pediatric parenteral nutrition formulations by neonatal intensive care units to sustain preterm infants immediately after birth. Institutional pharmacies have rapidly adopted ready-to-use multichamber bag systems to cut preparation times and lower compounding errors.
• Retail - The retail segment held a 15% share and is expected to grow in the coming years, driven by the shift of patients recovering from surgeries or managing long-term conditions away from hospitals to remote or home environments to reduce healthcare costs. Retail and online pharmacies make partnerships with nutrition manufacturers to offer direct-selling models. The integrated digital health platforms help in better tracking, ordering, and inventory management through retail pharmacy networks.

Competitive Landscape

Baxter International Inc. is dedicated to delivering customized and standard 3-chamber bag systems, specifically in intensive care settings, while Fresenius Kabi AG is a leading player in multi-chamber bag systems and lipid technology. B. Braun SE is a major player in

providing customized compounded parenteral nutrition and specialized amino acid formulations. The European industry is adopting digital integration and testing smart and connected pumps, and AI-powered dosing protocols to optimize delivery.

Segments Covered in the Report

By Nutrient Type

• Single Dose Amino Acid Solution
• Parenteral Lipid Emulsion
• Carbohydrates
• Trace Elements
• Vitamins and Minerals

By Stage Type

• Adult
• Pediatrics

By Indication

• Cancer Care
• Malabsorption/GI Disorder/Diarrhea
• Alzheimer's
• Nutrition Deficiency
• Diabetes
• Chronic Kidney Diseases
• Orphan Diseases
• Dysphagia
• Pain Management
• Others

By Sales Channel

• Institutional
• Retail
• Online